复星医药获批XS-03片临床试验

财中社
27 Feb

2月27日,复星医药(600196/02196)发布公告,控股子公司星盛新辉近日获得国家药品监督管理局批准,进行XS-03片与FOLFOX或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌的临床试验。该临床试验将在中国境内开展,标志着公司在新药研发方面的又一重要进展。XS-03为公司自主研发的小分子口服PLK1抑制剂,具有抑制肿瘤细胞增殖及促进肿瘤细胞凋亡的作用。到2025年1月,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10